Another cancer drug by Janssen unlikely to be available in Germany
Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,
Tag: AMNOG process
Federal Cabinet has agreed new law to stabilise SHI finances
Despite strong opposition and critique raised by almost all stakeholders, the draft law on the financial stabilization of statutory health insurance (GKV-FinStG),
AOK raises further critique on draft law to stabilise SHI finances
Recently, I wrote about the planned reforms that the German Health Minister, Karl Lauterbach, wants to introduce with the act to stabilise
German Health minister presents new draft of act to stabilise SHI fund finances
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version
What’s important to know about real-world evidence data collection in Germany?
In this post, I’ll summarise the key points on the real-world evidence data collection in Germany, that the G-BA can request since